Vesigen to Present New Preclinical Data on Ophthalmology Applications of Engineered ARMMs at 2024 ARVO Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #ARMMs--Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today announced that the Company will be presenting two posters sharing new preclinical data from its engineered ARMMs platform at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. The meeting will be held in Seattle, Washington from May 5-9. Vesigen’s technology compris